PL2089367T3 - Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego - Google Patents

Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego

Info

Publication number: PL2089367T3
Authority: PL; Poland
Prior art keywords: receptor antagonists; mineralocorticoid receptor; pyrazoline compounds; pyrazoline; compounds
Prior art date: 2006-10-31

Application number

PL07825488T

Other languages

English (en)

Inventor

Marvin Jay Meyers

Graciela Barbieri Arhancet

Xiangyang Chen

Susan Landis Hockerman

Scott Allen Long

Matthew William Mahoney

David Bruce Reitz

Joseph Gerace Rico

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-31

Filing date

2007-10-17

Publication date

2012-04-30

2007-10-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2012-04-30 Publication of PL2089367T3 publication Critical patent/PL2089367T3/pl

Links

229940083712 aldosterone antagonist Drugs 0.000 title 1
239000002394 mineralocorticoid antagonist Substances 0.000 title 1
150000003219 pyrazolines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL07825488T 2006-10-31 2007-10-17 Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego PL2089367T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86360606P	2006-10-31	2006-10-31
EP07825488A EP2089367B1 (en)	2006-10-31	2007-10-17	Pyrazoline compounds as mineralocorticoid receptor antagonists
PCT/IB2007/003207 WO2008053300A1 (en)	2006-10-31	2007-10-17	Pyrazoline compounds as mineralocorticoid receptor antagonists

Publications (1)

Publication Number	Publication Date
PL2089367T3 true PL2089367T3 (pl)	2012-04-30

Family

ID=39027523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07825488T PL2089367T3 (pl)	2006-10-31	2007-10-17	Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego

Country Status (40)

Country	Link
US (3)	US7781428B2 (pl)
EP (1)	EP2089367B1 (pl)
JP (1)	JP4977760B2 (pl)
KR (1)	KR101107800B1 (pl)
CN (1)	CN101541757A (pl)
AP (1)	AP2527A (pl)
AR (1)	AR063529A1 (pl)
AT (1)	ATE537151T1 (pl)
AU (1)	AU2007315884B2 (pl)
BR (1)	BRPI0717937A2 (pl)
CA (1)	CA2667966C (pl)
CL (1)	CL2007003154A1 (pl)
CO (1)	CO6160307A2 (pl)
CR (1)	CR10725A (pl)
CU (1)	CU23779B7 (pl)
CY (1)	CY1112311T1 (pl)
DK (1)	DK2089367T3 (pl)
EA (1)	EA016370B1 (pl)
ES (1)	ES2375877T3 (pl)
GE (1)	GEP20115239B (pl)
GT (1)	GT200700096A (pl)
HN (1)	HN2007000437A (pl)
HR (1)	HRP20120078T1 (pl)
IL (1)	IL198241A0 (pl)
MA (1)	MA30821B1 (pl)
MX (1)	MX2009004662A (pl)
MY (1)	MY145795A (pl)
NI (1)	NI200900071A (pl)
NO (1)	NO20091741L (pl)
NZ (1)	NZ575923A (pl)
PE (1)	PE20081472A1 (pl)
PL (1)	PL2089367T3 (pl)
PT (1)	PT2089367E (pl)
RS (2)	RS52203B (pl)
SI (1)	SI2089367T1 (pl)
TN (1)	TN2009000160A1 (pl)
TW (1)	TWI357327B (pl)
UA (1)	UA92670C2 (pl)
UY (1)	UY30670A1 (pl)
WO (1)	WO2008053300A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI431010B (zh)	2007-12-19	2014-03-21	Lilly Co Eli	礦皮質素受體拮抗劑及使用方法
WO2011059784A1 (en) *	2009-10-29	2011-05-19	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
ES2641144T3 (es)	2010-05-10	2017-11-07	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
WO2011141848A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
US9241944B2 (en)	2010-06-16	2016-01-26	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Methods and compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) *	2010-08-18	2012-03-14	山东轩竹医药科技有限公司	作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (en) *	2010-10-05	2012-04-12	Nova Southeastern University	Methods and compositions for therapeutic modulation of aldosterone levels in heart disease
RS58274B1 (sr)	2014-06-30	2019-03-29	Astrazeneca Ab	Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
US20180280414A1 (en)	2015-10-13	2018-10-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
WO2018019843A1 (en)	2016-07-26	2018-02-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018045149A1 (en)	2016-09-02	2018-03-08	Bristol-Myers Squibb Company	Substituted tricyclic heterocyclic compounds
WO2019032631A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	Oxime ether compounds
WO2019032632A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	ALKYLPHENYL COMPOUNDS
JP7697961B2 (ja)	2020-03-11	2025-06-24	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en)	2021-08-31	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of ocular rosacea
CN113679716B (zh)	2021-10-13	2024-03-26	史大永	溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) *	2022-01-04	2023-06-09	中山大学	一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1086068A (en) *	1964-09-02	1967-10-04	Ici Ltd	Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) *	1971-10-13	1973-04-11	Sandoz Sa	Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) *	1972-12-22	1974-06-11	Sandoz Ag	2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) *	1973-05-29	1974-10-22	Sandoz Ag	Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) *	1988-09-30	1989-09-12	Eastman Kodak Company	Thermally-transferable fluorescent diphenylpyrazolines
ES2098547T3 (es) *	1992-01-23	1997-05-01	Pfizer	Benzopirano y otros antagonistas de ltb4 relacionados.
GB9318691D0 (en)	1993-09-09	1993-10-27	Merck Sharp & Dohme	Therapeutic agents
AR006520A1 (es)	1996-03-20	1999-09-08	Astra Pharma Prod	Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
WO1998009969A1 (en) *	1996-09-05	1998-03-12	Astra Pharmaceuticals Ltd.	Novel aryl-pyridazines
JPH10273467A (ja) *	1997-01-29	1998-10-13	Snow Brand Milk Prod Co Ltd	新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it)	1997-06-05	1999-01-25	Geange Ltd	Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
WO1999055335A1 (en)	1998-04-30	1999-11-04	Basf Aktiengesellschaft	Substituted tricyclic pyrazole derivatives with protein kinase activity
US6432974B1 (en) *	2000-02-04	2002-08-13	Wyeth	Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
WO2003079973A2 (en)	2002-03-08	2003-10-02	Merck & Co., Inc.	Mitotic kinesin inhibitors
WO2003078394A1 (en)	2002-03-15	2003-09-25	Eli Lilly And Company	Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
DE60308387T2 (de)	2002-08-02	2007-09-20	Vertex Pharmaceuticals Inc., Cambridge	Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
PL375979A1 (pl)	2002-09-18	2005-12-12	Pfizer Products Inc.	Nowe związki pirazolowe jako inhibitory transformującego czynnika wzrostowego (TGF)
BRPI0406883A (pt)	2003-01-22	2006-01-03	Lilly Co Eli	Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MXPA06007055A (es) *	2003-12-19	2007-01-30	Lilly Co Eli	Moduladores del receptor nuclear de hormona esteroide triciclica.
JP2007230869A (ja)	2004-04-05	2007-09-13	Takeda Chem Ind Ltd	アルドステロン受容体拮抗剤
WO2006010142A2 (en)	2004-07-14	2006-01-26	Ligand Pharmaceuticals, Inc.	Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
EP1773768B8 (en)	2004-07-30	2018-12-26	Exelixis, Inc.	Pyrrole derivatives as pharmaceutical agents
EP1844020B1 (en)	2005-01-10	2017-09-06	Exelixis, Inc.	Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
JPWO2006077821A1 (ja)	2005-01-19	2008-06-19	大日本住友製薬株式会社	アルドステロン受容体調節剤としての芳香族スルホン化合物
US7595337B2 (en)	2005-02-10	2009-09-29	Merck & Co. Inc.	Mitotic kinesin inhibitors

2007
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active Expired - Fee Related
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-17 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 RS RS20120051A patent/RS52203B/sr unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en not_active Ceased
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
2009
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
2012
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown

Also Published As

Publication number	Publication date
UA92670C2 (ru)	2010-11-25
WO2008053300A1 (en)	2008-05-08
HRP20120078T1 (hr)	2012-02-29
AU2007315884B2 (en)	2012-10-04
JP4977760B2 (ja)	2012-07-18
AR063529A1 (es)	2009-01-28
CR10725A (es)	2009-05-12
KR101107800B1 (ko)	2012-01-25
MX2009004662A (es)	2009-05-22
CA2667966C (en)	2011-08-02
PT2089367E (pt)	2012-02-01
US20080167294A1 (en)	2008-07-10
CA2667966A1 (en)	2008-05-08
CO6160307A2 (es)	2010-05-20
CY1112311T1 (el)	2015-12-09
SI2089367T1 (sl)	2012-02-29
US20120035131A1 (en)	2012-02-09
CU23779B7 (es)	2012-02-15
CN101541757A (zh)	2009-09-23
NZ575923A (en)	2011-01-28
US20100280016A1 (en)	2010-11-04
CU20090058A7 (es)	2011-07-11
UY30670A1 (es)	2008-05-31
GEP20115239B (en)	2011-06-10
HN2007000437A (es)	2011-01-17
PE20081472A1 (es)	2008-10-18
BRPI0717937A2 (pt)	2013-12-03
RS52203B (sr)	2012-10-31
US7781428B2 (en)	2010-08-24
IL198241A0 (en)	2009-12-24
EP2089367A1 (en)	2009-08-19
NI200900071A (es)	2010-03-08
EA016370B1 (ru)	2012-04-30
DK2089367T3 (da)	2012-02-06
EA200970341A1 (ru)	2009-10-30
JP2010508257A (ja)	2010-03-18
CL2007003154A1 (es)	2008-05-09
NO20091741L (no)	2009-05-29
RS20090208A (sr)	2010-06-30
MY145795A (en)	2012-04-30
TN2009000160A1 (fr)	2010-10-18
EP2089367B1 (en)	2011-12-14
AP2009004822A0 (en)	2009-04-30
GT200700096A (es)	2010-07-15
TWI357327B (en)	2012-02-01
ES2375877T3 (es)	2012-03-07
ATE537151T1 (de)	2011-12-15
KR20090060371A (ko)	2009-06-11
MA30821B1 (fr)	2009-10-01
AU2007315884A1 (en)	2008-05-08
AP2527A (en)	2012-12-06
TW200822924A (en)	2008-06-01

Publication	Publication Date	Title
IL198241A0 (en)	2009-12-24	Pyrazoline compounds as mineralocorticoid receptor antagonists
IL198825A0 (en)	2010-02-17	Substituted diazepan compounds as orexin receptor antagonists
PT1981902E (pt)	2015-11-02	Antagonistas dos recetores nogo
EP2058304A4 (en)	2012-10-10	P2X4 RECEPTOR ANTAGONIST
ZA201001597B (en)	2012-09-29	Octahydropentalene compounds as chemokine receptor antagonists
EP2129654A4 (en)	2012-08-01	NEW ANTAGONISTS OF THE GLUCAGON RECEPTOR
EP2099454A4 (en)	2010-11-10	AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP2184278A4 (en)	2011-08-03	P2X4 RECEIVER ANTAGONIST
IL204823A0 (en)	2010-11-30	Heterocyclic compounds as crth2 receptor antagonists
IL184816A0 (en)	2007-12-03	2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL196587A0 (en)	2009-11-18	2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL198650A0 (en)	2010-02-17	Progesterone receptor antagonists
ZA200903334B (en)	2010-04-28	Substituted diazepan compounds as orexin receptor antagonists
IL201165A0 (en)	2010-05-17	CRIg ANTAGONISTS
EP2099300A4 (en)	2011-12-07	IL-8 RECEPTOR ANTAGONISTS
EP2010180A4 (en)	2010-10-13	IL-8 RECEPTOR ANTAGONISTS
IL198542A0 (en)	2010-02-17	2-aminoquinolines as 5-ht(5a)receptor antagonists
EP2153736A4 (en)	2011-08-24	NEW LEUKOTRIEN RECEPTOR ANTAGONIST
ZA200808766B (en)	2010-01-27	Nitrated heterocyclic compounds as endothelin receptor antagonist
ZA200904479B (en)	2010-09-29	Nitroderivatives as angiotensin II receptor antagonists
IL205949A0 (en)	2010-11-30	3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
ZA200903499B (en)	2010-03-31	Indoles which act as via receptor antagonists
IL195027A0 (en)	2009-08-03	Constrained compounds as cgrp-receptor antagonists
ZA200809205B (en)	2010-01-27	Constrained compounds as CGRP-receptor antagonists
ZA200802339B (en)	2009-10-28	Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists